Holen Sie sich die Stockscreener-App
1.67
1.21%
0.02
Handel nachbörslich:
1.67
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
H.C. Wainwright reiterates Buy rating on Biomea Fusion stock amid investor concerns By Investing.com - Investing.com Australia
How geopolitical tensions affect Biomea Fusion Inc. stockQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Real time pattern detection on Biomea Fusion Inc. stock2025 Market Trends & Fast Entry High Yield Stock Tips - newser.com
Is Biomea Fusion Inc. stock trading at a premium valuationPortfolio Growth Summary & Low Drawdown Trading Techniques - newser.com
Can Biomea Fusion Inc. stock hit analyst price targetsJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Is Biomea Fusion Inc. meeting your algorithmic filter criteriaJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Biomea Fusion Inc. stock retracement – recovery analysisWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Should you wait for a breakout in Biomea Fusion Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com
Biomea Fusion (NASDAQ:BMEA) Trading Up 6.5%What's Next? - MarketBeat
A Fresh Look at Biomea Fusion's (BMEA) Valuation Following Clinical Milestone and $25M Equity Raise - Sahm
Tools to assess Biomea Fusion Inc.’s risk profileMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Does Biomea Fusion Inc. fit your quant trading model2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
What analysts say about Biomea Fusion Inc stockBollinger Bands Signals & Free Unmatched Market Gains - earlytimes.in
Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance
Biomea Fusion Announces Positive Phase II Study Results - MSN
Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher - Benzinga
Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups - insights.citeline.com
Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com Nigeria
Biomea’s ‘durable’ menin inhibitor advancing in hard-to-treat diabetes - BioWorld MedTech
Biomea Fusion: Surging On Data, Sinking On FundingI'm On The Sidelines - Seeking Alpha
Traders Purchase High Volume of Biomea Fusion Call Options (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study - inkl
Dow Jumps Over 100 Points; McCormick Earnings Top Views - Benzinga
Biomea Fusion announces pricing of public offering of securities - MSN
Biomea Fusion plunges on $25 mln stock-and-warrants offering - TradingView
Biomea Fusion Announces Pricing of Public Offering of Securities - The Manila Times
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq
$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan
Biomea Fusion announces proposed public offering of securities - MarketScreener
Biomea Fusion, Inc. (BMEA) Stock: Volatile Surge Ahead of Jefferies-Led Equity Offering - parameter.io
Biomea's diabetes drug shows promise, may work for those not responding to GLP-1 - MarketScreener
Biomea announces positive 52-week results from phase II COVALENT-111 study in type 2 diabetes - MarketScreener
Biomea Fusion Reports Phase 2 Data in Diabetes, Launches Stock Offering - MarketScreener
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion launches public offering of common stock and warrants - Investing.com
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com Australia
Biomea Fusion reports 52-week results from Phase II diabetes trial - Investing.com
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Biomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes Patients - Quiver Quantitative
Biomea Fusion Announces Positive 52-Week Results from Phase - GlobeNewswire
1.8% HbA1c reduction sustained at Week 52 — Biomea Fusion's icovamenib shows durable benefit - Stock Titan
Why Biomea Fusion Inc. stock remains undervaluedTrade Risk Summary & Safe Entry Zone Identification - newser.com
Visualizing Biomea Fusion Inc. stock with heatmapsVolume Spike & Weekly High Potential Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Receives “Buy” Rating from D. Boral Capital - Defense World
BMEA: D. Boral Capital Maintains Buy Rating with $16 PT | BMEA S - GuruFocus
Biomea Fusion's (BMEA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biomea Fusion, Inc. reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):